Overview

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Pemetrexed